Abstract
AbstractBecause of its suitable decay characteristics and favourable chemical behaviour, 67Cu is considered to have potential for application in radionuclide therapy. This has led to increasing interest in biochemical, preclinical and clinical studies with 67Cu‐labelled radiopharmaceuticals.67Cu can be produced in accelerators by bombarding a natZn‐ (1) or 68Zn target with protons (2) or by bombarding 67Zn with neutrons in a high flux reactor (3). At the present time we produce up to 3.7 Gbq of 67Cu at the 72 MeV accelerator of the Paul Scherrer Institute by irradiating natZn. In order to scale up the 67Cu production, we evaluated the use of 68Zn and 70Zn. Cross sections were measured using the reactions 65Cu(p, n)65Zn of monitor foils (4), natZn(p, 2pxn)67Cu in the p‐energy‐range 67 to 12 MeV, 68Zn(p, 2p)67Cu in the p‐energy range 67 to 45MeV and 70Zn(p, 2p2n)67Cu (5) in the p‐energy range 45 to 12 MeV. Results indicate that the use of 68Zn as target instead of natZn leads to a 4.5 — fold increase in 67Cu production and that the use of 70Zn leads to a 10–20‐fold increase in the 20–30 MeV energy range.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
